Monitor for next data readouts: IMA402 combination data with ICI in melanoma/gynecologic cancers and IMA401 combo in lung cancer (2027). IMA203CD8 Phase 1/2 IIT in pediatric cancers (1H 2027). The Phase 3 SUPRAME trial for anzu-cel is the key near-term catalyst for the franchise.
Price Chart
Executive Summary
Immatics presented updated Phase 1b data for IMA402 PRAME bispecific and Phase 1 data for IMA203CD8 PRAME cell therapy at ESMO 2026. IMA402 achieved a 32% cORR and 91% 1-year OS rate in PRAME-high advanced melanoma, while IMA203CD8 showed a 55% cORR in gynecologic cancers at clinically relevant doses. The data support continued development across multiple solid tumor indications, but the company remains pre-revenue with no financial results disclosed.
Key Facts
- IMA402 achieved 32% cORR and 91% 1-year OS rate in PRAME-high advanced melanoma patients
- IMA402 median DOR of 12.5 months in PRAME-high melanoma
- IMA203CD8 showed 55% cORR and median DOR of 8.4 months in gynecologic cancers at clinically relevant doses
- IMA203CD8 demonstrated 41% cORR across all tumor types and dose levels
- No IMA402-related Grade 5 events and no ICANS reported; safety profiles manageable for both assets
- Phase 3 SUPRAME trial for anzu-cel in advanced melanoma is ongoing
- First data for IMA402 in combination with IMA401 in lung cancer expected in 2027
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech. Positive clinical data could support valuation re-rating if regulatory milestones are achieved.
Risk Factors
- Clinical data are preliminary and subject to further quality checks and source data verification
- Competition from other PRAME-targeting therapies and checkpoint inhibitors
- Regulatory and manufacturing risks for cell therapy and bispecific platforms
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $7.31 | awaiting T+5 | — | $7.15 (−2.19%) |
Oct 24, 2026 3d ago | Press Release | $7.31 | awaiting T+5 | — | $7.15 (−2.19%) |
Oct 23, 2026 3d ago | 6-K | $7.31 | awaiting T+5 | — | $7.15 (−2.19%) |
Aug 27, 2026 8w ago | Insider Buy | $9.45 $9.56 | ▲ +1.16% | ▲ +1.05% | $7.15 (−24.34%) |
Aug 26, 2026 8w ago | 6-K | $9.36 $9.46 | ▼ −1.07% | ▼ −0.80% | $7.15 (+23.61%) |
Aug 18, 2026 9w ago | 6-K | $9.09 $9.24 | ▲ +1.65% | ▲ +1.85% | $7.15 (−21.34%) |
Aug 18, 2026 9w ago | Press Release | $9.09 $9.24 | ▲ +1.65% | ▲ +1.85% | $7.15 (−21.34%) |
Jun 2, 2026 20w ago | 6-K | $10.04 $9.16 | ▼ −8.76% | ▼ −5.80% | $7.15 (−28.78%) |
Jun 1, 2026 21w ago | 6-K | $11.14 $9.79 | ▼ −12.12% | ▼ −9.37% | $7.15 (−35.82%) |
Jun 1, 2026 21w ago | Press Release | $11.14 $9.79 | ▼ −12.12% | ▼ −9.37% | $7.15 (−35.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers